title: Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
abstract: The employment of current treatments based on chemotherapy and immunotherapy leads to inmunosuppression. The presence of mutations or polymorphisms in genes related to immune system might involve an additional disadvantage. The aim of the present study was to analyze mannose-binding lectin (MBL-2 gene) mutations and their association with severe infections and event-free survival in patients diagnosed with follicular lymphoma, treated uniformly, in the clinical trial LNHF-03. The results of this trial showed impressive clinical efficacy but was complicated with 80 documented infectious episodes. Patients were classified into two genotypic groups, AA and AO/OO, based on their haplotypic inheritance. Neither the number of infectious episodes nor differences in event-free survival was found as a function of MBL-2 groups. Other factors, including the lymphoma malignancy and the immune alterations associated with the disease, should be considered responsible for this observation.
authors: Hospital 12 de Octubre, Madrid, Spain. jmartinezlo@yahoo.es
authors: Joaquin
authors: J
authors: Martínez-López
authors: Ana
authors: A
authors: Rivero
authors: Inmaculada
authors: I
authors: Rapado
authors: Carlos
authors: C
authors: Montalbán
authors: Jose
authors: J
authors: Paz-Carreira
authors: Miguel
authors: M
authors: Canales
authors: Rafael
authors: R
authors: Martínez
authors: Pedro
authors: P
authors: Sánchez-Godoy
authors: Alberto
authors: A
authors: Fernández de Sevilla
authors: Francisco J
authors: FJ
authors: Peñalver
authors: Marcos
authors: M
authors: Gonzalez
authors: Elena
authors: E
authors: Prieto
authors: Antonio
authors: A
authors: Salar
authors: Carmen
authors: C
authors: Burgaleta
authors: Jose A
authors: JA
authors: Queizán
authors: Maria J
authors: MJ
authors: Peñarrubia
authors: Maria D
authors: MD
authors: Monteagudo
authors: Carmen
authors: C
authors: Cabrera
authors: Javier
authors: J
authors: De la Serna
authors: José F
authors: JF
authors: Tomás
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D057239:Early Termination of Clinical Trials; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007239:Infections / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D008231:Lymphopenia / Q000139:chemically induced / Q000150:complications; D008297:Male; D037601:Mannose-Binding Lectin / Q000235:genetics*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D011446:Prospective Studies; D012306:Risk; D000069283:Rituximab; D013030:Spain / Q000453:epidemiology; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; C445619:MBL2 protein, human; D037601:Mannose-Binding Lectin; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine